ONCX $.02, phase 1 FDA trials for Cancer treatment.
With an O/S of just 176M, ONCX has a market cap of $3.5M.
Oncolix OTC: ONCX is a pharmaceutical company that is in phase one, of FDA clinical human trials for Cancer treatment.
Early funding for this research came from the Susan G. Komen Foundation and the U.S. Government.
Dr. Chen is the primary inventor of Prolanta™ and made significant contributions to the development of a growth hormone antagonist for the treatment of acromegaly, Somavert, that has received FDA approval and currently marketed by Pfizer NYSE: PFE.
Oncolix as a private company had completed several rounds of private offerings that are only available to accredited investors, family trusts, endowments and institutional investors.
Accredited investors to date include the Texas Emerging Technology Fund and the Ernest Mario Family Trust among others.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
The ONCX principal shareholder is the Greenville Health System, a private not-for-profit entity involved in clinical care, education and research.
Greenville Health has been providing health care solutions for over a century.
The biographies of Oncolix officers, Board of Directors and company advisors have been released to the public and are available on the company website.
The Oncolix Team. Management
\ Board Members
\ Prolanta Inventor
\ Company Advisors
Oncolix has a worldwide patent portfolio that is also available to view on the Oncolix website.
Leveraging these worldwide patents, Oncolix could be in a position to realize substantial gains in revenue and market capitalization.
ONCX is one to watch for 2018.
IMO and FWIW.